Vimian Group AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIMGF research report →
About the company
Vimian Group AB (publ) is an international enterprise focused on the animal health sector, organized into four distinct divisions: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers a range of proprietary diagnostic tools and treatments under its Nextmune brand, providing both prescription and non-prescription options for the preventive care and management of chronic conditions in companion animals. Through its Indical Bioscience brand, Vimian delivers sophisticated molecular and immunodiagnostic solutions for laboratories, specifically targeting veterinary applications for both livestock and companion animal health markets.
- CEO
- Alireza Tajbakhsh
- IPO
- 2022
- Employees
- 1,200
- HQ
- Stockholm, SE
Price Chart
- Market Cap
- $1.46B
- P/E
- 39.54
- P/S
- 3.33
- P/B
- 2.01
- EV/EBITDA
- 14.65
- Div Yield
- 0.00%
- Gross Margin
- 55.33%
- Op Margin
- 18.23%
- Net Margin
- 8.49%
- ROE
- 5.28%
- ROIC
- 5.45%
- Revenue
- $425.00M · 13.39%
- Net Income
- $31.30M · 69.19%
- EPS
- $0.06 · 69.49%
- Op Income
- $67.60M
- FCF YoY
- 106.38%
- 52W High
- $4.30
- 52W Low
- $2.68
- 50D MA
- $2.77
- 200D MA
- $2.84
- Beta
- 1.17
- Avg Volume
- 4.57K
Get TickerSpark's AI analysis on VIMGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our VIMGF coverage
Recent articles, reports, and earnings notes.
No research on VIMGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VIMGF report →Similar companies
Peers in the same neighborhood.